BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21205752)

  • 1. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
    Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
    J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
    Shimada A; Xu G; Toki T; Kimura H; Hayashi Y; Ito E
    Blood; 2004 Jan; 103(1):366. PubMed ID: 14684662
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
    Kiyoi H; Yamaji S; Kojima S; Naoe T
    Leukemia; 2007 Mar; 21(3):574-6. PubMed ID: 17252020
    [No Abstract]   [Full Text] [Related]  

  • 6. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
    Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
    Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 8. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
    Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
    Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
    Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
    Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
    Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
    Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
    Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
    Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factor GATA-1 and Down syndrome leukemogenesis.
    Muntean AG; Ge Y; Taub JW; Crispino JD
    Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 20. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.
    Harigae H; Xu G; Sugawara T; Ishikawa I; Toki T; Ito E
    Blood; 2004 Apr; 103(8):3242-3. PubMed ID: 15070711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.